These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3971360)

  • 1. Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation.
    Pollack A; Block NL; Stover BJ; Irvin GL
    Cancer Res; 1985 Mar; 45(3):1052-7. PubMed ID: 3971360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss.
    Humphries JE; Isaacs JT
    Cancer Res; 1982 Aug; 42(8):3148-56. PubMed ID: 7093958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone sensitivity of the R3327-G rat prostate adenocarcinoma: growth rate, DNA content, and hormone receptors.
    Pollack A; Irvin GL; Block NL; Lipton RM; Stover BJ; Claflin AJ
    Cancer Res; 1982 Jun; 42(6):2184-90. PubMed ID: 7074599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
    English HF; Heitjan DF; Lancaster S; Santen RJ
    Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma.
    Ip MM; Milholland RJ; Rosen F
    Cancer Res; 1980 Jul; 40(7):2188-93. PubMed ID: 7388787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
    Brändström A; Westin P; Bergh A; Cajander S; Damber JE
    Cancer Res; 1994 Jul; 54(13):3594-601. PubMed ID: 8012987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence.
    Myers RB; Oelschlager DK; Weiss HL; Frost AR; Grizzle WE
    J Urol; 2001 Mar; 165(3):1027-32. PubMed ID: 11176534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.
    Isaacs JT; Coffey DS
    Cancer Res; 1981 Dec; 41(12 Pt 1):5070-5. PubMed ID: 7307008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R3327 prostate adenocarcinoma clonogenic cells: epithelial properties and hormone response.
    Dibner JJ; Nakeff A
    J Natl Cancer Inst; 1983 Jun; 70(6):1057-66. PubMed ID: 6574275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinate loss of growth regulatory factors following castration of rats carrying the Dunning R3327 G prostatic tumor.
    Rubenstein M; Shaw M; Targonski P; McKiel CF; Dubin A; Guinan PD
    Clin Physiol Biochem; 1992; 9(2):47-50. PubMed ID: 1284786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
    Smolev JK; Heston WD; Scott WW; Coffey DS
    Cancer Treat Rep; 1977; 61(2):273-87. PubMed ID: 872132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quiescence in R3327-G rat prostate tumors after androgen ablation.
    Pollack A; Joon DL; Wu CS; Sikes C; Hasegawa M; Terry NH; White RA; Zagars GK; Meistrich ML
    Cancer Res; 1997 Jun; 57(12):2493-500. PubMed ID: 9192831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
    Ellis WJ; Isaacs JT
    Cancer Res; 1985 Dec; 45(12 Pt 1):6041-50. PubMed ID: 4063963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state.
    Oka H; Chatani Y; Kohno M; Kawakita M; Ogawa O
    Int J Urol; 2005 Oct; 12(10):899-905. PubMed ID: 16323984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo selection of androgen-insensitive cells in R3327-G rat prostate tumors: diethylstilbestrol diphosphate treatment versus orchiectomy.
    Pollack A; Block NL; Stover BJ; Irvin GL; Fuentes MP; Claflin AJ; Malinin TI
    J Natl Cancer Inst; 1983 May; 70(5):907-14. PubMed ID: 6573535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.